SYNLOGIC, INC.

Synlogic, Inc. and Caldera Therapeutics, Inc. announced a definitive merger agreement to combine in an all-stock transaction. The combined entity will operate as Caldera Therapeutics, focusing on advancing CLD-423, a bispecific antibody for inflammatory bowel disease. Concurrently, Caldera secured an upsized $278 million private placement from institutional investors, which is expected to fund operations through Phase 2 clinical trials and extend the cash runway into 2029. Upon closing, pre-merger Caldera equityholders are expected to own approximately 62.8% of the combined company, Synlogic equityholders 2.3%, and private placement investors 34.9%.

Synlogic, Inc. reported a net income of $681 thousand for the first quarter of 2026, an increase from $317 thousand in the prior year period. This net income was primarily driven by a $1.87 million gain from the change in fair value of purchase warrant liability, as the company's operating loss widened to $1.32 million. As of March 31, 2026, cash and cash equivalents stood at $14.11 million. The company continues to pursue strategic alternatives following the discontinuation of its lead Phase 3 trial and a significant corporate restructuring in February 2024, which reduced its workforce to one employee. Synlogic was delisted from Nasdaq in January 2026 and now trades on the OTCID Basic Market.

SYNLOGIC, INC. (SYBX) filed an amendment to its 10-K to include previously omitted Part III information, primarily focusing on Directors, Executive Officers, and Corporate Governance, as well as Executive Compensation. The amendment details the composition of the Board of Directors, their independence, and the roles and compensation of the executive officer, Mary Beth Dooley. It also notes that no cash bonuses or equity awards were granted in 2025 due to the discontinuation of a pivotal study and a significant workforce reduction.